Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis-Reference-Cited by-同舟云学术

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis

Published:2016-02-02 Issue:5 Volume:315 Page:469
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Bachert Claus¹,Mannent Leda²,Naclerio Robert M.³,Mullol Joaquim⁴,Ferguson Berrylin J.⁵,Gevaert Philippe⁶,Hellings Peter⁷,Jiao Lixia⁸,Wang Lin⁸,Evans Robert R.⁹,Pirozzi Gianluca⁸,Graham Neil M.⁹,Swanson Brian⁸,Hamilton Jennifer D.⁹,Radin Allen⁹,Gandhi Namita A.⁹,Stahl Neil⁹,Yancopoulos George D.⁹,Sutherland E. Rand¹⁰

Affiliation:

1. Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium2Clintec, Karolinska Institute, Stockholm, Sweden

2. Research and Development, Sanofi, Chilly Mazarin, France

3. University of Chicago, Chicago, Illinois

4. Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

5. University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

6. Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium

7. Laboratory of Experimental Immunology, Department of Otorhinolaryngology—Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium

8. Research and Development, Sanofi, Bridgewater, New Jersey

9. Regeneron Pharmaceuticals Inc, Tarrytown, New York

10. Immunology and Inflammation Development Franchise, Sanofi Research and Development, Cambridge, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 650 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of biologics in lung function and quality of life of patients with united airways disease: A systematic review;Journal of Allergy and Clinical Immunology: Global;2024-02

2. IL‐4/IL‐13 pathway in nasal type 2 inflammation: The central role and targeted therapy;Eye & ENT Research;2024-01-12

3. Imaging of chronic rhinosinusitis with nasal polyps in the era of biological therapies;Current Opinion in Allergy & Clinical Immunology;2024-01-11

4. Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence;Expert Opinion on Biological Therapy;2024-01-10

5. Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update;Brazilian Journal of Otorhinolaryngology;2024-01